{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:11:31Z","timestamp":1780539091351,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.bone.2005.05.007","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T16:10:15Z","timestamp":1121875815000},"page":"433-440","source":"Crossref","is-referenced-by-count":20,"title":["Biological properties and mechanism of action of ibandronate: Application to the treatment of osteoporosis"],"prefix":"10.1016","volume":"37","author":[{"given":"S.","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2005.05.007_bib1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2005.05.007_bib2","article-title":"Adherence to long-term therapies: evidence for action","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.bone.2005.05.007_bib3","first-page":"408","article-title":"Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study","volume":"72","author":"Eastell","year":"2003","journal-title":"Calcif. Tissue Int."},{"issue":"Suppl 1","key":"10.1016\/j.bone.2005.05.007_bib4","first-page":"S107","article-title":"Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care","volume":"15","author":"Sebaldt","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib6","first-page":"S48","article-title":"Adherence to osteoporosis therapies","volume":"12","author":"Finigan","year":"2001","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2005.05.007_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"Suppl 7","key":"10.1016\/j.bone.2005.05.007_bib9","article-title":"Clinical and economic impact of adherence to osteoporosis medication","volume":"14","author":"Caro","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib10","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1001\/archinte.151.10.2026","article-title":"A model of lifetime osteoporosis impact","volume":"151","author":"Chrischilles","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2005.05.007_bib11","first-page":"S529","article-title":"Compliance with alendronate treatment in an osteoporosis clinic","volume":"15","author":"Lombas","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9343(97)00467-1","article-title":"Compliance with treatment regimens in chronic asymptomatic diseases","volume":"102","author":"Miller","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2005.05.007_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0149-2918(04)90023-9","article-title":"Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study","volume":"26","author":"Turbi","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2005.05.007_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib15","first-page":"859","article-title":"Compliance of osteoporotic patients with different treatment regimens","volume":"5","author":"Segal","year":"2003","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.bone.2005.05.007_bib16","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.bone.2005.05.007_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2005.05.007_bib18","first-page":"50","article-title":"A medication use evaluation of alendronate: compliance with administration guidelines","volume":"18","author":"Mersfelder","year":"1999","journal-title":"Pharm. Pract. Manag. Q."},{"key":"10.1016\/j.bone.2005.05.007_bib19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a muticenter, randomized, open-label, cross-over study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2005.05.007_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","article-title":"Patients with osteoporosis prefer once weekly to once daily dosing with alendronate","volume":"48","author":"Kendler","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2005.05.007_bib21","article-title":"Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women","author":"Baroutsou","year":"2004","journal-title":"EULAR"},{"key":"10.1016\/j.bone.2005.05.007_bib22","first-page":"S677","article-title":"Assessing the relationship between bisphosphonate dosing regimen and treatment adherence among post-menopausal osteoporotic women","volume":"15","author":"Cramer","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2005.05.007_bib23","first-page":"S1325","article-title":"Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate","volume":"15","author":"Ettinger","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"Suppl 1","key":"10.1016\/j.bone.2005.05.007_bib24","first-page":"S172","article-title":"Medication persistence is better with weekly bisphosphonates, but it remains suboptimal","volume":"19","author":"Recker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2005.05.007_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2005.05.007_bib27","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/jbmr.5650091206","article-title":"Structural requirements for bisphosphonate actions in vitro","volume":"9","author":"van Beek","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jbmr.5650140212","article-title":"The pharmacology of bisphosphonates and new insights into their mechanisms of action","volume":"14","author":"Russell","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib30","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2005.05.007_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RAS","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib32","first-page":"235","article-title":"Structure\u2013activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bone.2005.05.007_bib33","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl 3","key":"10.1016\/j.bone.2005.05.007_bib35","first-page":"S77","article-title":"Understanding intermittent therapy: potency and persistence","volume":"13","author":"Russell","year":"2002","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01351831","article-title":"Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration","volume":"53","author":"Hyldstrup","year":"1993","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2005.05.007_bib37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2005.05.007_bib38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1023\/A:1011024200280","article-title":"Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration","volume":"18","author":"Mitchell","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S8756-3282(03)00033-4","article-title":"The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast","volume":"32","author":"Tanko","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2005.05.007_bib40","first-page":"289","article-title":"Ibandronate: serum kinetics, tissue distribution and binding to bone following intravenous bolus injection","volume":"70","author":"Bauss","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2005.05.007_bib41","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2005.05.007_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","article-title":"Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis","volume":"103","author":"Thi\u00e9baud","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bone.2005.05.007_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Safety"},{"key":"10.1016\/j.bone.2005.05.007_bib44","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1111\/j.1572-0241.2000.03258.x","article-title":"An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae","volume":"95","author":"Lanza","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bone.2005.05.007_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bone.2005.05.007_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2005.05.007_bib48","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/ndt\/12.12.2797","article-title":"Acute renal failure and alendronate","volume":"12","author":"Zazgornik","year":"1997","journal-title":"Nephrol. Dial Transplant."},{"key":"10.1016\/j.bone.2005.05.007_bib49","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000046123","article-title":"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases","volume":"89","author":"Janssen van Doorn","year":"2001","journal-title":"Nephron"},{"key":"10.1016\/j.bone.2005.05.007_bib50","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"10.1016\/j.bone.2005.05.007_bib51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.bone.2005.05.007_bib52","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib53","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/jc.2003-022029","article-title":"Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis","volume":"88","author":"Cooper","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2005.05.007_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women with osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib55","first-page":"S373","article-title":"Oral monthly ibandronate in postmenopausal bone loss: results from the Monthly Oral Pilot Study","volume":"18","author":"Reginster","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2005.05.007_bib56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/rheumatology\/keg205","article-title":"Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis","volume":"42","author":"Ringe","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2005.05.007_bib57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib58","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2005.05.007_bib59","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed i.v. ibandronate injections are associated with suboptimal antifracture postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2005.05.007_bib60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/ard.62.10.969","article-title":"Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women","volume":"62","author":"Stakkestad","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bone.2005.05.007_bib61","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos. Int."},{"issue":"Suppl 7","key":"10.1016\/j.bone.2005.05.007_bib62","first-page":"S74","article-title":"Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDS","volume":"14","author":"Delmas","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","article-title":"The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent administration in rats","volume":"191","author":"Pfister","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.bone.2005.05.007_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2005.05.007_bib65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women","volume":"254","author":"Tanko","year":"2003","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2005.05.007_bib66","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","article-title":"Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies","volume":"25","author":"Schimmer","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2005.05.007_bib67","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2005.05.007_bib68","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2005.05.007_bib69","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2005.05.007_bib70","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2005.05.007_bib71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328205002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328205002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T05:59:07Z","timestamp":1548309547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328205002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S8756328205002188"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2005.05.007","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}